Skip to content

Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)

Phase IB Randomized Controlled Double-Blind Trial of Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells Under Electromechanical Guidance for Therapeutic Angiogenesis

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00314366
Enrollment
21
Registered
2006-04-13
Start date
2006-04-30
Completion date
2023-08-24
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

stem cell, autologous, ischemia

Brief summary

Recent studies have suggested that it may be possible to grow new blood vessels (angiogenesis) to supply the heart muscle that is currently not getting enough blood. One theory is that a certain type of stem cell, aldehyde dehydrogenase bright stem cells, may stimulate the growth of new vessels. After a bone marrow procedure, the special cells are separated and then injected back into the heart around the area of damage with a special guidance and injection system. Once a patient meets all inclusion criteria and no exclusion criteria, he/she will be consented to the study and extensive baseline testing will be completed at St. Luke's Episcopal Hospital in Houston, Texas. Once all baseline criteria are met, the patient has his/her own bone marrow harvested and later injected, if randomized to receive active treatment. The day after the bone marrow harvest, the patient is taken to the cardiac catheterization lab where NOGA mapping is performed and the processed cells or placebo are injected under electromechanical guidance into the affected areas of the left ventricle. The patient is usually discharged home the next day and returns for follow-up at weeks 1 and 4, and months 3 and 6, and at one year unless there is a crossover and then he/she begins baseline again at 6 months and follow-up for one more year. Follow-up testing, including quality of life and NOGA mapping, is done at the time of injection, as well as at 6 months.

Detailed description

This is a phase I, double blind trial to evaluate the use of Aldehyde Dehydrogenase-Bright (ALDHbr) in ischemic cardiomyopathy patients. The study hypothesis is that transendocardial injections of autologous bone marrow cells in patients with end-stage ischemic heart disease is safe, can provide neovascularization, and can improve perfusion and myocardial contractility. The primary object of this study is to assess the safety of the ALDHbr cell injections. The efficacy will be based upon treadmill MVO2. A maximum of 60 patients will be enrolled in the study. At the end of 6 months, after the required testing has been completed, the patients will be told whether they were in the control group or not. The patients in the control group will be given the option to crossover and actually receive stem cell injection. At the time of crossover, which then becomes the baseline, patients will begin the follow-up with all testing including clinic visits for one year for a total of 18 months follow-up.

Interventions

Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.

OTHERControl (plasma)

Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.

Sponsors

CHI St. Luke's Health, Texas
CollaboratorOTHER
Aldagen
CollaboratorINDUSTRY
Texas Heart Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Canadian cardiovascular (CV) Class II-IV angina and/or congestive heart failure (CHF) symptoms * Ejection fraction less than or equal to 45% * Reversible perfusion defect on single photon emission computed tomography (SPECT) * Coronary artery disease (CAD) unable to be corrected by surgery (bypass) or intervention (stent) * Able to walk on treadmill * Hemodynamically stable

Exclusion criteria

* Age less than 18 or greater than 70 * Atrial fibrillation * Severe valve disease * History of cancer in last 5 years * HIV positive; hepatitis B or C positive. * Left ventricular wall thickness less than 8 mm * Recent heart attack within the last 30 days

Design outcomes

Primary

MeasureTime frameDescription
Safety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse EventsBaseline and 6 monthsSafety of cell injections was assessed by reviewing adverse events at 2 time points: Baseline (periprocedural period up to 2 weeks post-procedure) and at 6 months post-procedure. Major adverse events were adjudicated (hospitalization, arrhythmia, exacerbation of congestive HF \[CHF\], acute coronary syndrome, myocardial infarction, stroke, or death).

Secondary

MeasureTime frameDescription
Canadian Cardiovascular (CCS) Angina ScoreBaseline and 6 monthsClinical and functional assessment in endstage ischemic cardiomyopathy patients using Canadian Cardiovascular (CCS) Angina Score which indicates discomfort from angina (chest pain). Class I- Angina only during strenuous or prolonged activity Class II- Slight limitation, with angina only during vigorous physical activity Class III- Symptoms with everyday living activities (moderate limitation) Class IV- Inability to perform any activity without angina or angina at rest (severe limitation)
Echocardiography (EF)Percent (%)Baseline and 6 monthsClinical and functional assessment in endstage ischemic cardiomyopathy patients using Echocardiography measures ejection fraction(EF)as a percentage(%) of blood leaving the heart with each beat or contraction. It can provide information concerning structural characteristics and blood flow in the heart and blood vessels. A normal heart pumps 50-75% of the blood with each contraction.
Left Ventricular End-Systolic Volume (LVESV) (ml)baseline and 6 monthsClinical and functional assessment in endstage ischemic cardiomyopathy patients using Left Ventricular End-Systolic Volume (LVESV) when the blood moves from the ventricles to the atria during the contraction cycle. Measured as volume in milliliters (ml). Normal is approximately 60- 65 milliliters.
Left Ventricular End-Diastolic Volume (LVEDV)baseline and 6 monthsClinical and functional assessment in endstage ischemic cardiomyopathy patients using Left Ventricular End-Diastolic Volume (LVEDV)which is the volume of blood inside the left ventricle when the heart has completed its filling cycle. The volume of the left ventricle is measured during contraction and relaxation. Normal heart volume inside the left ventricle is about 140 milliliters.
Echocardiography Wall Motion Score Index (WMSI)baseline and 6 monthsClinical and functional assessment in endstage ischemic cardiomyopathy patients using Echocardiography Wall Motion Score Index (WMSI) as defined by the American Heart Association which allows detection of abnormalities in the heart wall or blood flowing through the heart. Using this model, the left ventricle is divided into 17 segments. Normal contracting Left Ventricle has WMSI of 1. Larger WMSI indicates higher degree of abnormalities (2 for hypokinetic, 3 for akinetic, 4 for dyskinetic, and 5 for aneurysmal). WMSI was calculated as the sum of scores divided by the total number of segments.
New York Heart Association (NYHA) ClassificationBaseline and 6 monthsClinical and functional assessment in endstage ischemic cardiomyopathy patients using New York Heart Association (NYHA)Classification and indicates extent of heart failure based on limitations in physical activity. Class I- No symptoms/limitation in ordinary physical activity (shortness of breath when walking, etc) Class II-Mild symptoms/slight limitation during ordinary activity Class III- Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV- Severe limitations in activity/experiences symptoms while at rest (bedbound)
Echocardiography (EF) Percent (%)baseline and 6 monthsClinical and functional assessment in endstage ischemic cardiomyopathy patients using Echocardiography measures ejection fraction(EF)as a percentage(%) of blood leaving the heart with each beat or contraction. It can provide information concerning structural characteristics and blood flow in the heart and blood vessels. A normal heart pumps 50-75% of the blood with each contraction.
Total Severity Score (Stress)baseline and 6 monthsFor the stress test, cardiac SPECT polar mapping (gated dual-isotope) is used to evaluate perfusion, compared against a database with a statistically significant number of polar maps of healthy hearts based on gender, data acquisition method, stress vs rest and type of data (i.e. perfusion, wall motion or wall thickening) using a clinically validated software package (J Nucl Med Technol 2006; 34:3-17). The basal and mid-ventricle heart wall is mapped by cylindrical sampling and apex mapped by spheric, cylindric and radial sampling. Total severity score during stress is the sum of blackout pixels in the blackout polar map of myocardial perfusion during stress using cardiac SPECT imaging (adding scores in different views), weighted by the number of SDs below the mean. Total severity score varies from 0 (normal) to several thousands although the upper limit is not well defined. A score greater than 1000 indicates poor perfusion.
Total Severity Score (Rest)baseline and 6 monthsFor the total severity score at rest, cardiac SPECT polar mapping (gated dual-isotope) is used to evaluate myocardial cardiac perfusion, compared against a database with a statistically significant number of polar maps of healthy hearts and compared based on gender, data acquisition method, stress vs rest and type of data (i.e. perfusion, wall motion or wall thickening) using a clinically validated software package (J Nucl Med Technol 2006; 34:3-17). The basal and mid-ventricle heart wall is mapped by cylindrical sampling and apex mapped by spheric, cylindric and radial sampling at rest. Total severity score at rest is the sum of blackout pixels in the rest blackout polar map of myocardial perfusion cardiac SPECT imaging (adding scores in different views), weighted by the number of SDs below the mean. Total severity score varies from 0 (normal) to several thousands although the upper limit is not well defined. A score greater than 1000 indicates poor perfusion.
Total Severity Score (Reversible)baseline and 6 monthsFor the severity test, cardiac SPECT polar mapping (gated dual-isotope) is used to evaluate myocardial cardiac perfusion, compared against a database with a statistically significant number of polar maps of healthy hearts and compared based on gender, data acquisition method, stress vs rest and type of data (i.e. perfusion, wall motion or wall thickening) using clinically validated software package (J Nucl Med Technol 2006; 34:3-17). The basal and mid-ventricle heart wall is mapped by cylindrical sampling and apex mapped by spheric, cylindric and radial sampling at rest/stress. Total severity score is the sum of blackout pixels in rest/stress blackout polar map of myocardial perfusion cardiac SPECT imaging (adding scores in different views), weighted by number of SDs below mean. Total severity score reversible is total severity scores at rest subtracted from those during stress. The severity score varies from 0 (normal) to \> 1000 (poor perfusion) but upper limit is not well defined.
Myocardial Oxygen Consumption (MVO2)baseline and 6 monthsClinical and functional assessment in endstage ischemic cardiomyopathy patients using Myocardial Oxygen Consumption (MVO2)which is the amount of oxygen used by the heart muscle and is indicative of heart muscle function. Normal value is 15.5 Volume %. Measured as milliliters (ml) oxygen per kilogram (kg) body weight per minute.

Countries

United States

Participant flow

Recruitment details

Twenty one patients were recruited between 9/1/06 and 8/6/08 from outpatient Cardiology clinics.

Participants by arm

ArmCount
Stem Cell Therapy
Subjects are randomized to receive Stem Cell Therapy (treatment) at the time of enrollment where cells are delivered after NOGA mapping and cells injected with the Myostar catheter. Stem Cell Therapy: Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
10
Control
Control (Placebo) patients will receive injections of plasma control instead of stem cells. Placebo patients are able to crossover and receive active treatment at 6 months if they meet the criteria. Plasma control: Placebo patients receive an injection of plasma containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
10
Total20

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall Studynot treated due to patient medical condi10

Baseline characteristics

CharacteristicTotalStem Cell TherapyControl
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
20 Participants10 Participants10 Participants
Age, Continuous
Age
58.0 years
STANDARD_DEVIATION 5.8
58.2 years
STANDARD_DEVIATION 6.1
57.8 years
STANDARD_DEVIATION 5.5
Region of Enrollment
United States
20 participants10 participants10 participants
Sex: Female, Male
Female
3 Participants1 Participants2 Participants
Sex: Female, Male
Male
17 Participants9 Participants8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
10 / 1010 / 10
serious
Total, serious adverse events
10 / 1010 / 10

Outcome results

Primary

Safety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Events

Safety of cell injections was assessed by reviewing adverse events at 2 time points: Baseline (periprocedural period up to 2 weeks post-procedure) and at 6 months post-procedure. Major adverse events were adjudicated (hospitalization, arrhythmia, exacerbation of congestive HF \[CHF\], acute coronary syndrome, myocardial infarction, stroke, or death).

Time frame: Baseline and 6 months

Population: The data was analyzed for all participants in control and treated groups.

ArmMeasureGroupValue (NUMBER)
ControlSafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse EventsNumber treated10 participants
ControlSafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventscerebrovascular event1 participants
ControlSafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse EventsEMM realted ventricular tachycardia2 participants
ControlSafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventsangina exacerbation1 participants
ControlSafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventsatrial arrhythmia0 participants
ControlSafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventsmyocardial infarction (NSTEMI)0 participants
ControlSafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse EventsEMM related ventricular fibrillation1 participants
ControlSafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventsintracardiac thrombus0 participants
Stem Cell TherapySafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse EventsEMM related ventricular fibrillation0 participants
Stem Cell TherapySafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse EventsNumber treated10 participants
Stem Cell TherapySafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventsatrial arrhythmia2 participants
Stem Cell TherapySafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse EventsEMM realted ventricular tachycardia0 participants
Stem Cell TherapySafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventsintracardiac thrombus1 participants
Stem Cell TherapySafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventscerebrovascular event0 participants
Stem Cell TherapySafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventsangina exacerbation5 participants
Stem Cell TherapySafety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Eventsmyocardial infarction (NSTEMI)1 participants
Secondary

Canadian Cardiovascular (CCS) Angina Score

Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Canadian Cardiovascular (CCS) Angina Score which indicates discomfort from angina (chest pain). Class I- Angina only during strenuous or prolonged activity Class II- Slight limitation, with angina only during vigorous physical activity Class III- Symptoms with everyday living activities (moderate limitation) Class IV- Inability to perform any activity without angina or angina at rest (severe limitation)

Time frame: Baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlCanadian Cardiovascular (CCS) Angina ScoreCCS baseline2.5 units on a scaleStandard Deviation 0.5
ControlCanadian Cardiovascular (CCS) Angina ScoreCCS 6 months2.0 units on a scaleStandard Deviation 0
Stem Cell TherapyCanadian Cardiovascular (CCS) Angina ScoreCCS baseline2.5 units on a scaleStandard Deviation 0.5
Stem Cell TherapyCanadian Cardiovascular (CCS) Angina ScoreCCS 6 months2.0 units on a scaleStandard Deviation 0.5
Secondary

Echocardiography (EF) Percent (%)

Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Echocardiography measures ejection fraction(EF)as a percentage(%) of blood leaving the heart with each beat or contraction. It can provide information concerning structural characteristics and blood flow in the heart and blood vessels. A normal heart pumps 50-75% of the blood with each contraction.

Time frame: baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlEchocardiography (EF) Percent (%)EF (%) baseline38.0 percentage of bloodStandard Deviation 17.5
ControlEchocardiography (EF) Percent (%)EF (%) 6 months40.4 percentage of bloodStandard Deviation 15.8
Stem Cell TherapyEchocardiography (EF) Percent (%)EF (%) baseline41.9 percentage of bloodStandard Deviation 11.8
Stem Cell TherapyEchocardiography (EF) Percent (%)EF (%) 6 months42.2 percentage of bloodStandard Deviation 7.6
Secondary

Echocardiography (EF)Percent (%)

Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Echocardiography measures ejection fraction(EF)as a percentage(%) of blood leaving the heart with each beat or contraction. It can provide information concerning structural characteristics and blood flow in the heart and blood vessels. A normal heart pumps 50-75% of the blood with each contraction.

Time frame: Baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlEchocardiography (EF)Percent (%)baseline36.1 percentage of bloodStandard Deviation 10.9
ControlEchocardiography (EF)Percent (%)6 months36.0 percentage of bloodStandard Deviation 11.3
Stem Cell TherapyEchocardiography (EF)Percent (%)baseline32.1 percentage of bloodStandard Deviation 10.6
Stem Cell TherapyEchocardiography (EF)Percent (%)6 months34.0 percentage of bloodStandard Deviation 9.3
Secondary

Echocardiography Wall Motion Score Index (WMSI)

Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Echocardiography Wall Motion Score Index (WMSI) as defined by the American Heart Association which allows detection of abnormalities in the heart wall or blood flowing through the heart. Using this model, the left ventricle is divided into 17 segments. Normal contracting Left Ventricle has WMSI of 1. Larger WMSI indicates higher degree of abnormalities (2 for hypokinetic, 3 for akinetic, 4 for dyskinetic, and 5 for aneurysmal). WMSI was calculated as the sum of scores divided by the total number of segments.

Time frame: baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlEchocardiography Wall Motion Score Index (WMSI)WMSI baseline1.91 units on a scaleStandard Deviation 0.51
ControlEchocardiography Wall Motion Score Index (WMSI)WMSI 6 months1.90 units on a scaleStandard Deviation 0.57
Stem Cell TherapyEchocardiography Wall Motion Score Index (WMSI)WMSI baseline2.13 units on a scaleStandard Deviation 0.38
Stem Cell TherapyEchocardiography Wall Motion Score Index (WMSI)WMSI 6 months2.06 units on a scaleStandard Deviation 0.41
Secondary

Left Ventricular End-Diastolic Volume (LVEDV)

Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Left Ventricular End-Diastolic Volume (LVEDV)which is the volume of blood inside the left ventricle when the heart has completed its filling cycle. The volume of the left ventricle is measured during contraction and relaxation. Normal heart volume inside the left ventricle is about 140 milliliters.

Time frame: baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlLeft Ventricular End-Diastolic Volume (LVEDV)LVDEV baseline138.3 mlStandard Deviation 43
ControlLeft Ventricular End-Diastolic Volume (LVEDV)LVDED 6 months127.2 mlStandard Deviation 51.3
Stem Cell TherapyLeft Ventricular End-Diastolic Volume (LVEDV)LVDEV baseline132.7 mlStandard Deviation 65.2
Stem Cell TherapyLeft Ventricular End-Diastolic Volume (LVEDV)LVDED 6 months131.3 mlStandard Deviation 67.4
Secondary

Left Ventricular End-Systolic Volume (LVESV) (ml)

Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Left Ventricular End-Systolic Volume (LVESV) when the blood moves from the ventricles to the atria during the contraction cycle. Measured as volume in milliliters (ml). Normal is approximately 60- 65 milliliters.

Time frame: baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlLeft Ventricular End-Systolic Volume (LVESV) (ml)LVESV baseline93.2 mlStandard Deviation 46.1
ControlLeft Ventricular End-Systolic Volume (LVESV) (ml)LVESV 6 months85.9 mlStandard Deviation 46.2
Stem Cell TherapyLeft Ventricular End-Systolic Volume (LVESV) (ml)LVESV baseline94.9 mlStandard Deviation 59.8
Stem Cell TherapyLeft Ventricular End-Systolic Volume (LVESV) (ml)LVESV 6 months94.7 mlStandard Deviation 62.2
Secondary

Myocardial Oxygen Consumption (MVO2)

Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Myocardial Oxygen Consumption (MVO2)which is the amount of oxygen used by the heart muscle and is indicative of heart muscle function. Normal value is 15.5 Volume %. Measured as milliliters (ml) oxygen per kilogram (kg) body weight per minute.

Time frame: baseline and 6 months

Population: data from 9 stem cell patients at 6 months, 10 at baseline

ArmMeasureGroupValue (MEAN)Dispersion
ControlMyocardial Oxygen Consumption (MVO2)MVO2 baseline15.5 ml/kg/minStandard Deviation 6.3
ControlMyocardial Oxygen Consumption (MVO2)MVO2 6 months17.7 ml/kg/minStandard Deviation 4.1
Stem Cell TherapyMyocardial Oxygen Consumption (MVO2)MVO2 baseline14.1 ml/kg/minStandard Deviation 4.8
Stem Cell TherapyMyocardial Oxygen Consumption (MVO2)MVO2 6 months14.6 ml/kg/minStandard Deviation 6.7
Secondary

New York Heart Association (NYHA) Classification

Clinical and functional assessment in endstage ischemic cardiomyopathy patients using New York Heart Association (NYHA)Classification and indicates extent of heart failure based on limitations in physical activity. Class I- No symptoms/limitation in ordinary physical activity (shortness of breath when walking, etc) Class II-Mild symptoms/slight limitation during ordinary activity Class III- Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV- Severe limitations in activity/experiences symptoms while at rest (bedbound)

Time frame: Baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlNew York Heart Association (NYHA) ClassificationNYHA baseline2.5 NYHA Functional classStandard Deviation 0.5
ControlNew York Heart Association (NYHA) ClassificationNYHA 6 months2.3 NYHA Functional classStandard Deviation 0.5
Stem Cell TherapyNew York Heart Association (NYHA) ClassificationNYHA baseline2.6 NYHA Functional classStandard Deviation 0.5
Stem Cell TherapyNew York Heart Association (NYHA) ClassificationNYHA 6 months2.1 NYHA Functional classStandard Deviation 0.3
Secondary

Total Severity Score (Rest)

For the total severity score at rest, cardiac SPECT polar mapping (gated dual-isotope) is used to evaluate myocardial cardiac perfusion, compared against a database with a statistically significant number of polar maps of healthy hearts and compared based on gender, data acquisition method, stress vs rest and type of data (i.e. perfusion, wall motion or wall thickening) using a clinically validated software package (J Nucl Med Technol 2006; 34:3-17). The basal and mid-ventricle heart wall is mapped by cylindrical sampling and apex mapped by spheric, cylindric and radial sampling at rest. Total severity score at rest is the sum of blackout pixels in the rest blackout polar map of myocardial perfusion cardiac SPECT imaging (adding scores in different views), weighted by the number of SDs below the mean. Total severity score varies from 0 (normal) to several thousands although the upper limit is not well defined. A score greater than 1000 indicates poor perfusion.

Time frame: baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlTotal Severity Score (Rest)Total Severity Score (rest) baseline542.8 units on a scaleStandard Deviation 440.7
ControlTotal Severity Score (Rest)Total Severity Score (rest) 6 months594.6 units on a scaleStandard Deviation 488.9
Stem Cell TherapyTotal Severity Score (Rest)Total Severity Score (rest) baseline812.4 units on a scaleStandard Deviation 304.5
Stem Cell TherapyTotal Severity Score (Rest)Total Severity Score (rest) 6 months828 units on a scaleStandard Deviation 396.9
Secondary

Total Severity Score (Reversible)

For the severity test, cardiac SPECT polar mapping (gated dual-isotope) is used to evaluate myocardial cardiac perfusion, compared against a database with a statistically significant number of polar maps of healthy hearts and compared based on gender, data acquisition method, stress vs rest and type of data (i.e. perfusion, wall motion or wall thickening) using clinically validated software package (J Nucl Med Technol 2006; 34:3-17). The basal and mid-ventricle heart wall is mapped by cylindrical sampling and apex mapped by spheric, cylindric and radial sampling at rest/stress. Total severity score is the sum of blackout pixels in rest/stress blackout polar map of myocardial perfusion cardiac SPECT imaging (adding scores in different views), weighted by number of SDs below mean. Total severity score reversible is total severity scores at rest subtracted from those during stress. The severity score varies from 0 (normal) to \> 1000 (poor perfusion) but upper limit is not well defined.

Time frame: baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlTotal Severity Score (Reversible)Total Severity Score (reversible) baseline72.6 units on a scaleStandard Deviation 95.2
ControlTotal Severity Score (Reversible)Total Severity Score (reversible) 6 months22.9 units on a scaleStandard Deviation 39.2
Stem Cell TherapyTotal Severity Score (Reversible)Total Severity Score (reversible) baseline46.5 units on a scaleStandard Deviation 48.5
Stem Cell TherapyTotal Severity Score (Reversible)Total Severity Score (reversible) 6 months87.3 units on a scaleStandard Deviation 60.2
Secondary

Total Severity Score (Stress)

For the stress test, cardiac SPECT polar mapping (gated dual-isotope) is used to evaluate perfusion, compared against a database with a statistically significant number of polar maps of healthy hearts based on gender, data acquisition method, stress vs rest and type of data (i.e. perfusion, wall motion or wall thickening) using a clinically validated software package (J Nucl Med Technol 2006; 34:3-17). The basal and mid-ventricle heart wall is mapped by cylindrical sampling and apex mapped by spheric, cylindric and radial sampling. Total severity score during stress is the sum of blackout pixels in the blackout polar map of myocardial perfusion during stress using cardiac SPECT imaging (adding scores in different views), weighted by the number of SDs below the mean. Total severity score varies from 0 (normal) to several thousands although the upper limit is not well defined. A score greater than 1000 indicates poor perfusion.

Time frame: baseline and 6 months

ArmMeasureGroupValue (MEAN)Dispersion
ControlTotal Severity Score (Stress)Stress Severity Score (stress) baseline798.2 units on a scaleStandard Deviation 528.7
ControlTotal Severity Score (Stress)Stress Severity Score (stress) 6 months785.9 units on a scaleStandard Deviation 554.6
Stem Cell TherapyTotal Severity Score (Stress)Stress Severity Score (stress) baseline1007.6 units on a scaleStandard Deviation 352.4
Stem Cell TherapyTotal Severity Score (Stress)Stress Severity Score (stress) 6 months1132 units on a scaleStandard Deviation 588.5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026